FHA
LTRN icon

Flagship Harbor Advisors’s Lantern Pharma LTRN Stock Holding History

Flagship Harbor Advisors’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-147,671
Closed -$2.68M – 663
2021
Q1 		$2.68M Buy
+147,671
New +$2.59M 0.3% 79

Other funds holding LTRN

CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $401M AUM 14.95% 1-Year Est. Return
WWM
Wolff Wiese Magana Carslbad, California $217M AUM 47.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Flagship Harbor Advisors's LTRN Position: Q2 2021 in Review

Flagship Harbor Advisors sold out of Lantern Pharma (LTRN) in Q2 2021, closing a stake of 147,671 shares — an estimated $2.68M sold.

Flagship Harbor Advisors first reported a position in LTRN in Q1 2021 and held it in 1 quarter. The position peaked at $2.68M in Q1 2021. 22 funds tracked by Wall St. Rank hold LTRN as of Q2 2021.

  • Flagship Harbor Advisors reported no remaining Lantern Pharma position as of Q2 2021 after selling out during the quarter.
  • Flagship Harbor Advisors sold 147,671 Lantern Pharma shares in Q2 2021, an estimated $2.68M.
  • Flagship Harbor Advisors first reported a position in Lantern Pharma in Q1 2021 and held it in 1 quarter.
  • Flagship Harbor Advisors's Lantern Pharma position peaked at $2.68M in Q1 2021.
  • 22 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2021.

Based on Flagship Harbor Advisors's 13F filing for Q2 2021, filed 26 Jul 2021.